Mauricio Mauricio Tohen: Influence Statistics

Mauricio Mauricio Tohen

Mauricio Mauricio Tohen

Department of Psychiatry & Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM, United States. | Department of Psychiatry and Behavioral ...

Mauricio Mauricio Tohen: Expert Impact

Concepts for which Mauricio Mauricio Tohen has direct influence: Bipolar disorder , Bipolar depression , Acute mania , Bipolar mania , Patients bipolar disorder , Bipolar disorders , Bipolar choice .

Mauricio Mauricio Tohen: KOL impact

Concepts related to the work of other authors for which for which Mauricio Mauricio Tohen has influence: Bipolar disorder , Atypical antipsychotics , Patients schizophrenia , Weight gain , Mental health , Acute mania , Depressive symptoms .

KOL Resume for Mauricio Mauricio Tohen

Year
2021

Department of Psychiatry & Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM, United States.

2020

Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, New Mexico

International Consortium for Mood & Psychotic Disorders, Mailman Research Center, McLean Hospital, Belmont, MA, USA

2019

Department of Psychiatry & Behavioral Sciences, University of New Mexico, Albuquerque, New Mexico

2018

Department of Psychiatry & Behavioral Sciences, University of New Mexico, Health Sciences Center, 87131, Albuquerque, NM, USA

The authors are members of the Editorial Board of the Journal.

2017

The American Psychiatric Association Task Force on Biomarkers and Novel Treatments, USA

2016

Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.

2015

University of New Mexico Department of Psychiatry Albuquerque NM USA

2014

Department of Psychiatry University of New Mexico School of Medicine Albuquerque NM

2013

University of New Mexico, Health Science Center, Department of Psychiatry, Albuquerque, NM, USA

2012

Division of Mood and Anxiety Disorders, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Department of Psychiatry, University of Texas Health Science Center at San Antonio TXUSA

University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

2011

Department of Psychiatry, The University of Texas Health Science Center at San Antonio, TX, USA

University of Texas Health Science Center at San Antonio, United States

International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA

Prominent publications by Mauricio Mauricio Tohen

KOL-Index: 17748 . OBJECTIVE: Since stability of DSM-IV diagnoses of disorders with psychotic features requires validation, we evaluated psychotic patients followed systematically in the McLean-Harvard International First Episode Project. METHOD: We diagnosed 517 patients hospitalized in a first psychotic illness by SCID-based criteria at baseline and at 24 months to assess stability of specific DSM-IV ...
Known for Psychotic Disorder | Major Diagnosis | Episode Project | Harvard International
KOL-Index: 17174 . OBJECTIVE: A cavum between the septi pellucidi may reflect neurodevelopmental anomalies in midline structures of the brain. The authors examined cavum septi pellucidi in subjects with schizophrenia, affective disorder, and schizotypal personality disorder and in normal subjects. METHOD: Thirty schizophrenic patients (15 chronic, 15 first-episode), 16 patients with affective disorder ...
Known for Affective Disorder | Septi Pellucidi | Schizotypal Personality | Mri Study
KOL-Index: 16351 . There are no rapid-acting intramuscular formulations of atypical antipsychotics available for quickly calming an agitated patient with bipolar disorder. In this study, 201 agitated patients with bipolar mania were randomly assigned to receive one to three injections of the atypical antipsychotic olanzapine (10 mg, first two injections; 5 mg, third injection), the benzodiazepine lorazepam ...
Known for Bipolar Mania | Intramuscular Injections | Olanzapine Lorazepam | Agitation Patients
KOL-Index: 15848 . BACKGROUND: To evaluate the 12-week outcomes (effectiveness, tolerability, and patterns of medication use) of olanzapine (either in antimanic monotherapy or in combination with other antipsychotics, anticonvulsants, and/or lithium) in patients with bipolar mania or mixed mania. METHOD: EMBLEM (European Mania in Bipolar Longitudinal Evaluation of Medication) is a 24-month prospective ...
Known for Olanzapine Monotherapy | European Mania | Combination Therapy | Bipolar Longitudinal
KOL-Index: 14511 . OBJECTIVE: Few long-term studies have compared the efficacy and safety of typical and atypical antipsychotic medications directly in patients with a first episode of psychosis who met the criteria for schizophrenia or a related psychotic disorder. This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a ...
Known for Episode Psychosis | Olanzapine Patients | Versus Haloperidol | Comparative Efficacy
KOL-Index: 13910 . OBJECTIVE: The authors compared the efficacy of olanzapine and lithium in the prevention of mood episode relapse/recurrence. METHOD: Patients with a diagnosis of bipolar disorder (manic/mixed), a history of two or more manic or mixed episodes within 6 years, and a Young Mania Rating Scale total score > or =20 entered the study and received open-label co-treatment with olanzapine and ...
Known for Olanzapine Lithium | Bipolar Disorder | Maintenance Treatment | Relapse Recurrence
KOL-Index: 13784 . OBJECTIVE: The effect of antipsychotic medication on neurocognitive function remains controversial, especially since most previous work has compared the effects of novel antipsychotic medications with those of high doses of conventional medications. This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis. METHOD: ...
Known for Episode Psychosis | Haloperidol Patients | Effects Treatment | Low Doses
KOL-Index: 13273 . OBJECTIVE: The effects of olanzapine and divalproex for the treatment of mania were compared in a large randomized clinical trial. METHOD: A 3-week, randomized, double-blind trial compared flexibly dosed olanzapine (5-20 mg/day) to divalproex (500-2500 mg/day in divided doses) for the treatment of patients hospitalized for acute bipolar manic or mixed episodes. The Young Mania Rating Scale ...
Known for Treatment Olanzapine | Acute Mania | Dry Mouth | Rating Scale
KOL-Index: 13269 . BACKGROUND: In chronic schizophrenia, the P300 is broadly reduced and shows a localized left temporal deficit specifically associated with reduced gray matter volume of the left posterior superior temporal gyrus (STG). In first-episode patients, a similar left temporal P300 deficit is present in schizophrenia, but not in affective psychosis. The present study investigated whether the left ...
Known for Episode Schizophrenia | Magnetic Resonance Imaging | Affective Psychosis | Temporal Gyrus
KOL-Index: 12819 . BACKGROUND: A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared with valproate or lithium alone in treating acute manic or mixed bipolar episodes. METHODS: The primary objective was to evaluate the efficacy of olanzapine (5-20 mg/d) vs placebo when added to ongoing ...
Known for Lithium Treatment | Efficacy Olanzapine | Patients Bipolar Disorder | Partially Nonresponsive
KOL-Index: 12587 . OBJECTIVES: Unipolar and bipolar depression differ neurobiologically and in clinical presentation. Existing depression rating instruments, used in bipolar depression, fail to capture the necessary phenomenological nuances, as they are based on and skewed towards the characteristics of unipolar depression. Both clinically and in research there is a growing need for a new observer-rated ...
Known for Bipolar Depression | Rating Scale | Statistical Female Humans | Madrs Ymrs
KOL-Index: 12555 . OBJECTIVE: It has been hypothesized that the morbidity and mortality associated with schizophrenia can be prevented by providing effective treatment during the first episode of psychosis. Hence, the authors examined patients with first-episode psychosis to determine the efficacy and safety of olanzapine and haloperidol treatment. METHOD: A subpopulation of first-episode patients (N=83) ...
Known for Episode Psychosis | Haloperidol Treatment | Olanzapine Treated | Onset Illness
KOL-Index: 12538 . BACKGROUND: Improving patients' health-related quality of life (HRQOL) could be a treatment goal for bipolar depression. OBJECTIVES: The objectives of these secondary analyses of a previous report were to determine the benefits of olanzapine alone and olanzapine-fluoxetine combination (OFC) for improving HRQOL in patients with bipolar depression using both a generic and a ...
Known for Bipolar Depression | Mental Health | Life Hrqol | Fluoxetine Combination

Key People For Bipolar Disorder

Top KOLs in the world
#1
Eduardo Eduard
bipolar disorder cognitive impairment acute mania
#2
Robert M Post
bipolar disorder affective illness depressed patients
#3
Susan L McElroy
bipolar disorder binge eating bulimia nervosa
#4
Paul E Keck
bipolar disorder acute mania united states
#5
Joseph R Calabrese
bipolar disorder suicidal ideation rapid cycling
#6
Gary S Sachs
bipolar disorder rapid cycling acute mania

Department of Psychiatry & Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM, United States. | Department of Psychiatry and Behavioral Sciences, School of Medicine, University of New Mexico, Albuquerque, New Mexico